Skip header and navigation

5 records – page 1 of 1.

Clostridium sordellii toxic shock syndrome after medical abortion with mifepristone and intravaginal misoprostol--United States and Canada, 2001-2005.

https://arctichealth.org/en/permalink/ahliterature173601
Source
MMWR Morb Mortal Wkly Rep. 2005 Jul 29;54(29):724
Publication Type
Article
Date
Jul-29-2005
Source
MMWR Morb Mortal Wkly Rep. 2005 Jul 29;54(29):724
Date
Jul-29-2005
Language
English
Publication Type
Article
Keywords
Abortifacient Agents - administration & dosage - adverse effects
Abortion, Induced - adverse effects
Canada - epidemiology
Clostridium Infections - epidemiology - etiology
Clostridium sordellii
Female
Humans
Mifepristone - administration & dosage - adverse effects
Misoprostol - administration & dosage - adverse effects
Pregnancy
Shock, Septic - epidemiology - etiology
United States - epidemiology
Abstract
On July 19, 2005, the Food and Drug Administration (FDA) issued a public health advisory regarding the deaths of four women in the United States after medical abortions with Mifeprex (mifepristone, formerly RU-486; Danco Laboratories, New York, New York) and intravaginal misoprostol. Two of these deaths occurred in 2003, one in 2004, and one in 2005. Two of these U.S. cases had clinical illness consistent with toxic shock and had evidence of endometrial infection with Clostridium sordellii, a gram-positive, toxin-forming anaerobic bacteria. In addition, a fatal case of C. sordellii toxic shock syndrome after medical abortion with mifepristone and misoprostol was reported in 2001, in Canada. All three cases of C. sordellii infection were notable for lack of fever, and all had refractory hypotension, multiple effusions, hemoconcentration, and a profound leukocytosis. C. sordellii previously has been described as a cause of pregnancy-associated toxic shock syndrome.
PubMed ID
16049422 View in PubMed
Less detail

Home use of two doses of misoprostol after mifepristone for medical abortion: a pilot study in Sweden and France.

https://arctichealth.org/en/permalink/ahliterature63129
Source
Eur J Contracept Reprod Health Care. 2005 Sep;10(3):184-91
Publication Type
Article
Date
Sep-2005
Author
W H Clark
D. Hassoun
K. Gemzell-Danielsson
C. Fiala
B. Winikoff
Author Affiliation
Gynuity Health Projects, New York, USA.
Source
Eur J Contracept Reprod Health Care. 2005 Sep;10(3):184-91
Date
Sep-2005
Language
English
Publication Type
Article
Keywords
Abortifacient Agents - administration & dosage - adverse effects
Abortion, Induced - methods
Adult
Female
France
Humans
Middle Aged
Mifepristone - administration & dosage - adverse effects
Misoprostol - administration & dosage - adverse effects
Patient satisfaction
Pilot Projects
Pregnancy
Sweden
Abstract
OBJECTIVE: To test the feasibility, safety, and efficacy of home use of two doses of misoprostol for medical abortion (MA) in European settings. METHODS: One hundred thirty women (100 in Sweden, 30 in France) presenting for first-trimester MA were administered oral mifepristone in the clinic and sent home with two 400 microg doses of misoprostol, along with instructions to take the misoprostol at 24 h intervals. Women were also asked to complete a daily symptom diary. Outcomes of interest included effectiveness, side-effects, and adherence to and acceptability of the home-use regimen. RESULTS: Three women (all in France) were lost to follow-up. Of the remaining 127 women, 124 (98%) had a successful MA. All women adhered successfully to the home-use regimen, and satisfaction with home use was high (98%). Most women experienced noticeable, if transitory, side effects after both the first and second doses of misoprostol (97% and 94%, respectively). CONCLUSIONS: Misoprostol may successfully and satisfactorily be used at home as part of a MA regimen in European settings as it has been for years in the US. Further research to determine if two doses of misoprostol are more effective than a single dose would be useful.
PubMed ID
16318966 View in PubMed
Less detail

[Medical abortion is as safe as surgical abortion]

https://arctichealth.org/en/permalink/ahliterature64262
Source
Lakartidningen. 1997 Sep 17;94(38):3257-60
Publication Type
Article
Date
Sep-17-1997

Medical abortions in adolescent girls.

https://arctichealth.org/en/permalink/ahliterature116682
Source
Prescrire Int. 2012 Dec;21(133):303
Publication Type
Article
Date
Dec-2012
Source
Prescrire Int. 2012 Dec;21(133):303
Date
Dec-2012
Language
English
Publication Type
Article
Keywords
Abortifacient Agents - administration & dosage - adverse effects
Abortion, Induced - adverse effects - statistics & numerical data
Adolescent
Adult
Age Factors
Female
Finland
France
Humans
Retrospective Studies
Abstract
According to a retrospective Finnish study, the adverse effects of medical abortion do not appear more common in girls under the age of 18 years than in adult women.
PubMed ID
23373102 View in PubMed
Less detail

Safety and efficacy of mid-term pregnancy termination using aglepristone in dogs.

https://arctichealth.org/en/permalink/ahliterature89776
Source
J Small Anim Pract. 2009 Mar;50(3):120-3
Publication Type
Article
Date
Mar-2009
Author
Pettersson C H
Tidholm A.
Author Affiliation
Albano Animal Hospital, Rinkebyvägen 23, 182 36 Danderyd, Sweden.
Source
J Small Anim Pract. 2009 Mar;50(3):120-3
Date
Mar-2009
Language
English
Publication Type
Article
Keywords
Abortifacient Agents - administration & dosage - adverse effects - standards
Abortion, Induced - adverse effects - veterinary
Animals
Dogs
Estrenes - administration & dosage - adverse effects - standards
Female
Follow-Up Studies
Gestational Age
Pregnancy
Questionnaires
Sweden
Treatment Outcome
Ultrasonography, Prenatal - veterinary
Abstract
OBJECTIVES: To investigate effects and side effects of aglepristone in terminating pregnancy in bitches. METHODS: Twenty-two bitches were treated in mid-pregnancy with subcutaneous injections of aglepristone at a total dose of 20 mg/kg. Short-term follow-up (one to two weeks after treatment) included clinical examination and abdominal ultrasonography in 18 of the dogs. Long-term telephone follow-up was recorded for all 22 dogs. RESULTS: Pregnancy was terminated in 21 bitches (95 per cent). Signs of abortion occurred one to eight days after treatment. Vaginal discharge was evident in 17 (77 per cent) dogs. Obvious signs of parturition were seen in nine (41 per cent) dogs. Eight dogs (36 per cent) developed anorexia, and in two (9 per cent) of the dogs a local reaction at the injection site was evident. Two dogs developed pyometra two and four years after treatment, respectively. CLINICAL SIGNIFICANCE: Aglepristone, when administered in mid-gestation, is effective in terminating pregnancy. Side effects are few and transient.
PubMed ID
19261081 View in PubMed
Less detail